Mecasermin

Mecasermin — ADMETatlas

5. Exposure / Absorption

What evidence describes systemic exposure or absorption?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Bioavailability Cmax Tmax AUC

Bioavailability, AUC, Cmax, and Tmax evidence.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	~ 100 %	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Mecasermin· 12.3 Pharmacokinetics · mecasermin absolute bioavailability healthy subjects...	Open

AUC

Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.

6. Distribution / Barrier

What is known about distribution, binding, permeability, or barrier crossing?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Plasma protein binding Vd

Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	0.257 L/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Route: subcutaneous · Mecasermin· 12.3 Pharmacokinetics · mecasermin table1 vd f mean · Table 1. Summary of INC...	Open

Plasma protein binding

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.

7. Metabolic & Proteolytic Stability

How stable is the peptide in biological matrices or protease systems?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Serum/plasma stability

Serum/plasma stability and protease stability evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Comparable measurements

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability6 measurements · 4 comparable · 2 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	< 15 minutes < 900 seconds	Comparable	Radioimmunoassay · (Dose i/v injected)Chicken plasma	Dose/window: 6 - 10 μg/Kg · Time: Blood collected 12hours after peptide injection · Proteases from chicken plasma · in vivo	Open
2	100 minutes 6000 seconds	Comparable	Radioimmunoassay · rat · Rat Serum	Dose/window: 1 μCi peptide injected to rhesus monkey · Time: Blood collected 10 minutes to 6 hours after peptide injection · Proteases from Rat serum · in vivo	Open
3	0.8 hours 2880 seconds	Comparable	Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity · Eight merino lambs plasma	Dose/window: 10mM/L · Time: Blood collected 10 minutes to 30 hours after peptide infusion · Lamb plasma proteases · in vivo	Open
4	6 hours 21600 seconds	Comparable	Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity · Eight merino lambs plasma	Dose/window: 10mM/L · Time: Blood collected 10 minutes to 30 hours after peptide infusion · Lamb plasma proteases · in vivo	Open
5	Observation 6.0-7.0	Reported	Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity · Eight merino lambs plasma	Dose/window: 10mM/L · Time: Blood collected 10 minutes to 30 hours after peptide infusion · Lamb plasma proteases · in vivo	Open
6	Observation 0.8-0.9	Reported	Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity · Eight merino lambs plasma	Dose/window: 10mM/L · Time: Blood collected 10 minutes to 30 hours after peptide infusion · Lamb plasma proteases · in vivo	Open

Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.

8. Excretion / Persistence

What evidence describes clearance or persistence?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Half Life Clearance

Clearance and half-life evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	0.0424 L/h/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Route: subcutaneous · Mecasermin· 12.3 Pharmacokinetics · mecasermin table1 cl f mean · Table 1. Summary of INC...	Open

Half Life

Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.

Evidence landscape and measurement index

Evidence landscape

A cross-domain view of where evidence is concentrated, which interpretation layers dominate, and how traceable the measurements are.

ADMET domain

Comparable

Reported

Contextual

Exposure / Absorption

4 measurements

Distribution / Barrier

2 measurements

Metabolic & Proteolytic Stability

6 measurements

Excretion / Persistence

23 measurements

Toxicity / Safety

0 measurements

Endpoint distribution

Top evidence-bearing endpoint questions.

Half Life

Serum Plasma Stability

Area Under Curve

Bioavailability

Clearance

Max Concentration

Plasma Protein Binding

Time To Max Concentration

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every measurement remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainLayerReferenceSpeciesMatrixRoute

#	ADMET domain	Endpoint	Reported value	Evidence layer	Assay / model	Condition	Reference
1	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	Observation 6.0-7.0	Contextual	Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity · Eight merino lambs plasma	Time: Blood collected 10 minutes to 30 hours after peptide infusion · Dose/window: 10mM/L · Protease: Lamb plasma proteases · in vivo	Open
2	Excretion / Persistence Persistence	Half Life	8 minutes 480 seconds	Comparable	TCA precipitation · rat · Rat Stomach luminal flushing	Time: 5, 10, 20, 30 or 60 min · Dose/window: 8.6ng · Protease: Rat Stomach luminal flushing proteases · in vitro	Open
3	Excretion / Persistence Persistence	Half Life	Observation 0.971 ±0.336 (t1/2 β)	Contextual	TCA precipitation · rat · Intravenous injection into rat	Time: 1, 5, 15, and 30 min and at 1, 2, 4, 8, and 24 h · Dose/window: 15 μCi(0.2 ml) · Protease: Rat blood proteases · in vivo	Open
4	Excretion / Persistence Persistence	Half Life	38 minutes 2,280 seconds	Comparable	TCA precipitation · rat · Rat Colon luminal flushing	Time: 5, 10, 20, 30 or 60 min · Dose/window: 8.6ng · Protease: Rat Colon luminal flushing proteases · in vitro	Open
5	Excretion / Persistence Persistence	Half Life	2 minutes 120 seconds	Comparable	Antibody assay · rat · Rat Duodenum luminal flushing	Time: 2-5, 5, 7-5, 10 or 20min · Dose/window: 8.6ng · Protease: Rat Duodenum luminal flushing proteases · in vitro	Open
6	Excretion / Persistence Persistence	Half Life	Observation 203 ±10.2 (t1/2β)	Contextual	Radioimmunoassay and bi-exponential equation that describes a two-compartment model · rat · Intravenous bolus administr...	Time: 5, 30, 120 and 240 min · Dose/window: 100 μl · Protease: Rat blood proteases · in vivo	Open
7	Excretion / Persistence Persistence	Half Life	Observation 8.97 ±4.50 (t1/2 γ)	Contextual	TCA precipitation · rat · Intravenous injection into rat	Time: 1, 5, 15, and 30 min and at 1, 2, 4, 8, and 24 h · Dose/window: 15 μCi(0.2 ml) · Protease: Rat blood proteases · in vivo	Open
8	Excretion / Persistence Persistence	Half Life	33 minutes 1,980 seconds	Comparable	Antibody assay · rat · Rat Colon luminal flushing	Time: 5, 10, 20, 30 or 60 min · Dose/window: 8.6ng · Protease: Rat Colon luminal flushing proteases · in vitro	Open
9	Excretion / Persistence Persistence	Half Life	2 minutes 120 seconds	Comparable	Receptor-precipitable radioactivity · rat · Rat Ileum luminal flushing	Time: 2-5, 5, 7-5, 10 or 20min · Dose/window: 8.6ng · Protease: Rat Ileum luminal flushing proteases · in vitro	Open
10	Excretion / Persistence Persistence	Half Life	16 minutes 960 seconds	Comparable	Receptor-precipitable radioactivity · rat · Rat Colon luminal flushing	Time: 5, 10, 20, 30 or 60 min · Dose/window: 8.6ng · Protease: Rat Colon luminal flushing proteases · in vitro	Open

1–10 / 35

Identity & reference map

Summary7 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 7
Measurements: 35
ATL peptide ID: ATLPC0011025

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

29 / 29

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 29

Different notation

Reported notation does not resolve to the current display sequence.

0 / 29

Reference map7 of 7 shown

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
PubMed 7561632 Open	Persistence Half Life	No reported alias GPETLCGAELVDALQFVCG...CDLRRLEMYCAPLKPAKSAexact	12 identity 12 evidence
PubMed 11145579 Open	Persistence Half Life	No reported alias GPETLCGAELVDALQFVCG...CDLRRLEMYCAPLKPAKSAexact	6 identity 6 evidence
PubMed 3379352 Open	Stability Serum Plasma Stability	No reported alias GPETLCGAELVDALQFVCG...CDLRRLEMYCAPLKPAKSAexact	4 identity 4 evidence
PubMed 10607940 Open	Persistence Half Life	No reported alias GPETLCGAELVDALQFVCG...CDLRRLEMYCAPLKPAKSAexact	4 identity 4 evidence
Reference link Open	DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +3 more	No reported alias GPETLCGAELVDALQFVCG...CDLRRLEMYCAPLKPAKSAexact	1 identity 7 evidence
PubMed 2454805 Open	Stability Serum Plasma Stability	No reported alias GPETLCGAELVDALQFVCG...CDLRRLEMYCAPLKPAKSAexact	1 identity 1 evidence
PubMed 3108068 Open	Stability Serum Plasma Stability	No reported alias GPETLCGAELVDALQFVCG...CDLRRLEMYCAPLKPAKSAexact	1 identity 1 evidence

Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.

Data access & reproducibility

Record scopePublic release

ATL peptide ID: ATLPC0011025
Identity type: canonical sequence
ADMET endpoints: 9
Measurements: 35
Reference groups: 7
Release view: Public release

Analysis-ready files

Peptide record

TSV

Identity, sequence, profile-level fields, and current release view metadata.

Download record

Programmatic access

The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.

Open endpoint

GET /api/v1/peptides/ATLPC0011025

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0011025' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.

#	Value	Evidence layer	Assay / model	Condition	Reference
1	2932 ng*h/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Route: subcutaneous · Mecasermin· 12.3 Pharmacokinetics · mecasermin table1 auc 0 8 mean · Table 1. Summary of...	Open

Cmax1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	234 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Route: subcutaneous · Mecasermin· 12.3 Pharmacokinetics · mecasermin table1 cmax mean · Table 1. Summary of INC...	Open

Tmax1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	2 hr 7200 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Route: subcutaneous · Mecasermin· 12.3 Pharmacokinetics · mecasermin table1 tmax mean · Table 1. Summary of INC...	Open

#	Value	Evidence layer	Assay / model	Condition	Reference
1	> 80 %	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · blood	Mecasermin· 12.3 Pharmacokinetics · mecasermin blood igf binding protein bound percent ·...	Open

#	Value	Evidence layer	Assay / model	Condition	Reference
1	33 minutes 1980 seconds	Comparable	Antibody assay · rat · Rat Colon luminal flushing	Dose/window: 8.6ng · Time: 5, 10, 20, 30 or 60 min · Rat Colon luminal flushing proteases · in vitro	Open
2	2 minutes 120 seconds	Comparable	Antibody assay · rat · Rat Duodenum luminal flushing	Dose/window: 8.6ng · Time: 2-5, 5, 7-5, 10 or 20min · Rat Duodenum luminal flushing proteases · in vitro	Open
3	2 minutes 120 seconds	Comparable	Antibody assay · rat · Rat Ileum luminal flushing	Dose/window: 8.6ng · Time: 2-5, 5, 7-5, 10 or 20min · Rat Ileum luminal flushing proteases · in vitro	Open
4	5 minutes 300 seconds	Comparable	Antibody assay · rat · Rat Stomach luminal flushing	Dose/window: 8.6ng · Time: 5, 10, 20, 30 or 60 min · Rat Stomach luminal flushing proteases · in vitro	Open
5	16 minutes 960 seconds	Comparable	Receptor-precipitable radioactivity · rat · Rat Colon luminal flushing	Dose/window: 8.6ng · Time: 5, 10, 20, 30 or 60 min · Rat Colon luminal flushing proteases · in vitro	Open
6	2 minutes 120 seconds	Comparable	Receptor-precipitable radioactivity · rat · Rat Duodenum luminal flushing	Dose/window: 8.6ng · Time: 2-5, 5, 7-5, 10 or 20min · Rat Duodenum luminal flushing proteases · in vitro	Open
7	2 minutes 120 seconds	Comparable	Receptor-precipitable radioactivity · rat · Rat Ileum luminal flushing	Dose/window: 8.6ng · Time: 2-5, 5, 7-5, 10 or 20min · Rat Ileum luminal flushing proteases · in vitro	Open
8	2.5 minutes 150 seconds	Comparable	Receptor-precipitable radioactivity · rat · Rat Stomach luminal flushing	Dose/window: 8.6ng · Time: 5, 10, 20, 30 or 60 min · Rat Stomach luminal flushing proteases · in vitro	Open
9	38 minutes 2280 seconds	Comparable	TCA precipitation · rat · Rat Colon luminal flushing	Dose/window: 8.6ng · Time: 5, 10, 20, 30 or 60 min · Rat Colon luminal flushing proteases · in vitro	Open
10	2 minutes 120 seconds	Comparable	TCA precipitation · rat · Rat Duodenum luminal flushing	Dose/window: 8.6ng · Time: 2-5, 5, 7-5, 10 or 20min · Rat Duodenum luminal flushing proteases · in vitro	Open

1–10 / 22

Mecasermin

Peptide developability profile

1. Sequence & peptidoform

Sequence interpretation

2. Structure & chemistry

Structure and chemistry interpretation

3. Physicochemical profile

Computed descriptors

Computed developability descriptors

4. Product context

Translational product context

5. Exposure / Absorption

Evidence summary

6. Distribution / Barrier

Evidence summary

7. Metabolic & Proteolytic Stability

Evidence summary

8. Excretion / Persistence

Evidence summary

9. Evidence landscape

Evidence landscape and measurement index

10. Identity & reference map

Identity & reference map

11. Data access & reproducibility

Data access & reproducibility

Peptide record

Evidence table

Structured record